📊 VKTX Key Takeaways
Is Viking Therapeutics, Inc. (VKTX) a Good Investment?
Viking Therapeutics is a pre-revenue clinical-stage biotech burning $278.7M annually with only 7-9 months of cash runway remaining at current burn rates. While the balance sheet is pristine with $165.8M cash and zero debt, the company faces imminent dilution risk and extreme execution risk dependent entirely on pipeline success with no revenue diversification.
Why Buy Viking Therapeutics, Inc. Stock? VKTX Key Strengths
- Strong balance sheet: $639.1M equity with zero long-term debt
- Excellent liquidity position: 9.33x current ratio provides operational flexibility
- Substantial cash reserves of $165.8M for near-term R&D funding
VKTX Stock Risks: Viking Therapeutics, Inc. Investment Risks
- Critical cash runway: $278.7M annual burn depletes reserves in <9 months, necessitating near-term financing and shareholder dilution
- Zero revenue generation: Complete pipeline dependency with no commercial product revenue or diversification
- Extreme execution risk: Clinical development success is binary and uncertain; lack of commercial validation or partnership deals
Key Metrics to Watch
- Monthly cash burn rate and updated runway estimates
- Clinical trial enrollment progress and FDA milestone announcements
- Capital raise activities and dilution impact on shareholder equity
Viking Therapeutics, Inc. (VKTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.33x current ratio provides a solid financial cushion.
VKTX Profit Margin, ROE & Profitability Analysis
VKTX vs Healthcare Sector: How Viking Therapeutics, Inc. Compares
How Viking Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Viking Therapeutics, Inc. Stock Overvalued? VKTX Valuation Analysis 2026
Based on fundamental analysis, Viking Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Viking Therapeutics, Inc. Balance Sheet: VKTX Debt, Cash & Liquidity
VKTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Viking Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.91 indicates the company is currently unprofitable.
VKTX Revenue Growth, EPS Growth & YoY Performance
VKTX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$24.9M | $-0.22 |
| Q2 2025 | N/A | -$22.3M | $-0.20 |
| Q1 2025 | N/A | -$27.4M | $-0.26 |
| Q3 2024 | N/A | -$22.5M | $-0.22 |
| Q2 2024 | N/A | -$19.2M | $-0.19 |
| Q1 2024 | N/A | -$19.5M | $-0.25 |
| Q3 2023 | N/A | -$15.8M | $-0.21 |
| Q2 2023 | N/A | -$17.4M | $-0.19 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Viking Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
VKTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Viking Therapeutics, Inc. (CIK: 0001607678)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VKTX
What is the AI rating for VKTX?
Viking Therapeutics, Inc. (VKTX) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VKTX's key strengths?
Claude: Strong balance sheet: $639.1M equity with zero long-term debt. Excellent liquidity position: 9.33x current ratio provides operational flexibility.
What are the risks of investing in VKTX?
Claude: Critical cash runway: $278.7M annual burn depletes reserves in <9 months, necessitating near-term financing and shareholder dilution. Zero revenue generation: Complete pipeline dependency with no commercial product revenue or diversification.
What is VKTX's revenue and growth?
Viking Therapeutics, Inc. reported revenue of $0.0.
Does VKTX pay dividends?
Viking Therapeutics, Inc. does not currently pay dividends.
Where can I find VKTX SEC filings?
Official SEC filings for Viking Therapeutics, Inc. (CIK: 0001607678) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VKTX's EPS?
Viking Therapeutics, Inc. has a diluted EPS of $-3.19.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is VKTX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Viking Therapeutics, Inc. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is VKTX stock overvalued or undervalued?
Valuation metrics for VKTX: ROE of -56.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy VKTX stock in 2026?
Our dual AI analysis gives Viking Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VKTX's free cash flow?
Viking Therapeutics, Inc.'s operating cash flow is $-278.7M, with capital expenditures of N/A.
How does VKTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -56.3% (avg: 15%), current ratio 9.33 (avg: 2).